title: Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning?
abstract: Because interruptions of antiretroviral treatment may entail clinical risks for human immunodeficiency virus (HIV)-infected individuals, we investigated their impact on neurocognitive functioning. Cross-sectional study was carried out, comparing HIV-infected persons who had interrupted antiretroviral therapy in the past (interruption group, IG) with persons who had never discontinued therapy (noninterruption group, NIG). Interruption was defined as the discontinuation of highly active antiretroviral therapy (HAART) for more than 15 days after previous treatment of at least 15 days. All the participants were on therapy. Demographic, clinical, and neurocognitive variables were assessed. The primary end point was the percentage of people with neurocognitive impairment. The score in different neurocognitive domains was a secondary end point. A total of 83 subjects participated in the study (IG: n = 27; NIG: n = 56). Demographic and clinical characteristics were balanced between the groups, except for years since HIV diagnosis (IG, 13.8; NIG, 10.2 [P = .003]). The percentage of people with neurocognitive impairment was significantly higher in the IG group (IG, 59.25%; NIG, 33.92% [P = 0.02]). As for scores in neurocognitive domains, individuals in the IG showed worse neurocognitive functioning, and significant differences in attention/working memory and information processing speed were found. The adjusted analysis supported the unadjusted analysis. In this study, a higher prevalence of neurocognitive impairment was detected in HIV-infected persons who had interrupted antiretroviral therapy in the past. Additionally, neurocognitive functioning was observed to be more impaired in the same individuals. Further studies should examine the potential negative effects of antiretroviral therapy interruptions on neurocognitive functioning.
authors.affiliation: Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Badalona, Barcelona, Catalonia, Spain. jmunoz@flsida.org
authors.forename: Jose A
authors.initials: JA
authors.lastname: Muñoz-Moreno
authors.forename: Carmina R
authors.initials: CR
authors.lastname: Fumaz
authors.forename: Anna
authors.initials: A
authors.lastname: Prats
authors.forename: Maria J
authors.initials: MJ
authors.lastname: Ferrer
authors.forename: Eugènia
authors.initials: E
authors.lastname: Negredo
authors.forename: Núria
authors.initials: N
authors.lastname: Pérez-Alvarez
authors.forename: José
authors.initials: J
authors.lastname: Moltó
authors.forename: Guadalupe
authors.initials: G
authors.lastname: Gómez
authors.forename: Maite
authors.initials: M
authors.lastname: Garolera
authors.forename: Bonaventura
authors.initials: B
authors.lastname: Clotet
mesh_terms: D000328:Adult; D044966:Anti-Retroviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D023241:Antiretroviral Therapy, Highly Active; D003072:Cognition Disorders / Q000175:diagnosis / Q000453:epidemiology / Q000821:virology*; D003430:Cross-Sectional Studies; D004334:Drug Administration Schedule; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D015995:Prevalence; D012749:Sexually Transmitted Diseases / Q000188:drug therapy / Q000453:epidemiology; D013375:Substance Withdrawal Syndrome; D016312:Treatment Refusal
chemical_list: D044966:Anti-Retroviral Agents
references.citation: J Neurovirol. 2005 Jul;11(3):265-73
references.pmid: 16036806
references.citation: AIDS. 2001 Jun 15;15(9):F29-40
references.pmid: 11416735
references.citation: AIDS. 2008 Aug 20;22(13):1583-8
references.pmid: 18670217
references.citation: N Engl J Med. 2006 Nov 30;355(22):2283-96
references.pmid: 17135583
references.citation: AIDS Res Hum Retroviruses. 2008 Oct;24(10):1301-7
references.pmid: 18844464
references.citation: J Neurovirol. 2004 Dec;10(6):350-7
references.pmid: 15765806
references.citation: AIDS. 2004 Jan 1;18 Suppl 1:S11-8
references.pmid: 15075493
references.citation: J Neurovirol. 2004 Aug;10(4):223-32
references.pmid: 15371152
references.citation: AIDS. 2009 Apr 27;23(7):757-9
references.pmid: 19307943
references.citation: AIDS. 1999 May 28;13(8):F59-62
references.pmid: 10371167
references.citation: J Neurovirol. 2008 Nov;14(6):550-7
references.pmid: 19016380
references.citation: J Infect Dis. 2002 Sep 15;186(6):851-4
references.pmid: 12198623
references.citation: Viral Immunol. 2005;18(3):579-81
references.pmid: 16212537
references.citation: Clin Infect Dis. 2005 Jul 1;41 Suppl 1:S38-44
references.pmid: 16265612
references.citation: Neurology. 2006 May 9;66(9):1447-50
references.pmid: 16682686
references.citation: Assessment. 1999 Jun;6(2):147-78
references.pmid: 10335019
references.citation: J Acquir Immune Defic Syndr. 2007 Jun 1;45(2):174-82
references.pmid: 17356465
references.citation: Neurology. 2007 Oct 30;69(18):1789-99
references.pmid: 17914061
references.citation: AIDS. 2002 May 3;16(7):1083-4
references.pmid: 11953480
references.citation: J Infect Dis. 2003 Jun 1;187(11):1818-21
references.pmid: 12751041
references.citation: Ann Neurol. 1997 Nov;42(5):679-88
references.pmid: 9392566
references.citation: J Med Virol. 2009 Mar;81(3):481-7
references.pmid: 19152399
references.citation: J Neurovirol. 2004;10 Suppl 1:44-51
references.pmid: 14982739
references.citation: AIDS. 2007 Jan 11;21(2):169-78
references.pmid: 17197807
references.citation: N Engl J Med. 2001 Feb 15;344(7):472-80
references.pmid: 11172188
references.citation: J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):56-63
references.pmid: 19731418
references.citation: Brain. 2006 Feb;129(Pt 2):503-16
references.pmid: 16317019
references.citation: J Neurovirol. 2002 Apr;8(2):136-42
references.pmid: 11935465
references.citation: Neurology. 2000 Feb 22;54(4):921-6
references.pmid: 10690987
references.citation: J Neurovirol. 2007 Jun;13(3):225-32
references.pmid: 17613712
references.citation: J Infect Dis. 2005 Mar 15;191(6):890-8
references.pmid: 15717264
references.citation: AIDS Res Hum Retroviruses. 2004 Dec;20(12):1283-8
references.pmid: 15650419
references.citation: Lancet. 2006 Jun 17;367(9527):1981-9
references.pmid: 16782488
references.citation: AIDS Res Hum Retroviruses. 2005 Aug;21(8):706-13
references.pmid: 16131310
references.citation: Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15109-14
references.pmid: 10611346
references.citation: AIDS. 2009 Apr 27;23(7):799-807
references.pmid: 19114869
references.citation: AIDS. 2004 Feb 20;18(3):439-46
references.pmid: 15090796
references.citation: AIDS. 2009 Jun 19;23(10):1187-95
references.pmid: 19455015
references.citation: Arch Neurol. 2002 Jun;59(6):923-8
references.pmid: 12056927
references.citation: J Clin Invest. 2005 Feb;115(2):443-50
references.pmid: 15668739
references.citation: AIDS Res Hum Retroviruses. 1999 Jun 10;15(9):811-20
references.pmid: 10381169
references.citation: Clin Infect Dis. 2005 Feb 15;40(4):594-600
references.pmid: 15712083
references.citation: Arch Neurol. 2008 Jan;65(1):65-70
references.pmid: 18195140
references.citation: Ann Neurol. 2004 Sep;56(3):416-23
references.pmid: 15349869
references.citation: AIDS Rev. 2008 Oct-Dec;10(4):236-44
references.pmid: 19092979
references.citation: Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13747-52
references.pmid: 12370434
references.citation: Neurology. 2006 Jun 13;66(11):1688-95
references.pmid: 16769942